Dr. Berman talks about his research in fat stem cells.
Most people (doctors included) believe that stem cell therapy is still several years away from being available to the public. However, since 2010, in association with my partner, urologist Elliot Lander, MD, FACS, we have been conducting stem cell deployment as part of an ongoing investigative project collecting data on thousands of treated patients. After several successful outcomes in the orthopedic arena that I obtained in collaboration with orthopedic surgeon, Dr. Tom Grogan, Elliot and I formed the California Stem Cell Treatment Center followed a year later by the Cell Surgical Network the worlds largest network of stem cell physicians utilizing technology we developed with renown Korean plastic surgeon, Dr. Lee Hee Young. We currently teach doctors from the USA and worldwide our techniques using the CSN Time Machine to effectively harvest and process fat into stromal vascular fraction (SVF) rich in stem cells. Starting with a 10 minute mini-liposuction painlessly done under local anesthesia, this 1 hour process has yielded results that have been successfully recapitulated all over the world. Currently, there are about 100 CSN centers in the US and many more throughout the world, including dozens in China in association with our partners, RE Stem Biotech.
We are now in a new era of medicine. Our bodies are made up of dozens of trillions of cells. Up until now, medicine was predominantly aimed at keeping our cells healthy and alive through diet, exercise, medications to eradicate disease, or supplements to help our cells stay healthy, but now, going forward, we have the opportunity to replace injured or dying cells with our own DNA coded stem cells. These cells can not cause an allergic response or be rejected. While many people consider this experimental, we really consider it investigational but not really experimental. This may be a NEW era in medicine, but it really reflects perhaps the OLDEST form of intervention. Before we had any kind of medical intervention we had to rely on our bodys natural cell defense to keep us healthy. We now have the ability to unlock and harvest huge quantities of these repair cells for immediate use and, further, we can send samples to our lab where they can be cryopreserved and expanded as millions of stem cells for later use. Indeed, we have coined the term CRT Cell Renewal Therapy to describe how we foresee the future of medicine whereby your natural spare parts in the form of your own DNA cultivated stem cells will be made available to keep your body healthy and extend longevity for years beyond anything ever imaginable.
Stem cells are basically unspecialized cells that can replicate and differentiate (i.e. turn into other specialized cells). They tend to have three basic properties: 1) anti-inflammatory; 2) immune-modulatory and 3) reparative or regenerative. Most people think an embryo is the most common source for stem cells. While most stem cell studies started by using embryos, there are a number of issues and problems associated with their use. Not only are there ethical concerns, embryonic stem cells can sometimes form tumors (i.e. teratomas).
There are also a lot of stem cells naturally found in our body. Most people are aware of bone marrow derived stem cells. In recent years, bone marrow has been a source for stem cells particularly for orthopedic conditions. However, stem cell yields in bone marrow tend to be between 50,000 and 200,000 with some of the newer technology. Adipose (fat) tissue also houses vast quantities of stem cells. In fact, just 30 ccs (2 tablespoons) of fat can yield between 10 and 30 million stem cells.
Our fat derived stem cells have a tremendous capacity to turn into a large variety of tissues. Originally, because of their mesenchymal origin we thought they could only turn into fat, cartilage, bone, muscle, connective tissue, blood vessels and nerve tissue, but now we have studies showing theyve turned into practically every kind of cell in the body. While the bone marrow proponents will sing the virtues of bone marrow stem cells for cartilage repair, it turns out that fat derived cells are an even greater source for cartilage repair and production. Compared to a bone marrow harvest, its so simple to harvest a little fat and the yields are generally very high making fat an ideal source for stem cells.
When we started our studies in 2010 the critics suggested it might not be safe. Our initial study made SAFETY the primary objective and the clinical outcomes a secondary objective. Our safety study of over 1500 patients has shown that there are no significant adverse events related to the deployment of SVF. Indeed, the only real issues have been some mild discomfort around the liposuction site something we naturally expect. Weve submitted this paper for publication.
While there are a growing number of doctors claiming to provide stem cell treatments, we believe the most ethical approach is to do it under the umbrella of IRB approved research protocols. An IRB is an Institutional Review Board or an organization of members responsible for approving and overseeing research on humans. IRBs are approved under the auspices of the U.S. Department of Human Research Protection. As such, our patients understand the investigational nature of our activities, are provided appropriate informed consents, and are followed continuously on an online database to chart their progress or any issues of concern. This will allow us to not only accumulate safety data but demonstrate effectiveness of treatments and help us to improve treatment programs going forward.
We already have a number of very innovative treatments in progress. For example, one of our approved studies involves deployment of cells via an Ommaya reservoir. This is a device that connects a port under the scalp via a tube directly into the ventricle of the brain where cells can be added to the cerebral spinal fluid. This concept evolved by working with renown Brain Surgeon, Christopher Duma, MD, FACS. It was preceded by safety studies on laboratory rats and 30 patients later is showing some significant progress.
As you can imagine, with new technologies, patients often come to you when theyve exhausted most other traditional treatments. Weve now had a lot of experience to understand how well cell therapy can work even though were continuing to gather data and look for ways of optimizing treatments. So, for example, most patients with arthritic knees will consider stem cell deployment after theyve tried pain medication, steroids, hyaluronan injections and even arthroscopy. None of these are actually treatments that repair the problem but rather mask the pain or temporize the situation. If theres cartilage in the knee then it can potentially signal your stem cells to repair the joint. We now understand that acute injuries probably respond better than chronic ones because there are more messages (cytokines) directing and instructing the stem cells into action and repair. Still, until we have enough data and publish enough articles to support these positions our concepts remain conjecture awaiting to be proven.
Patients are also concerned about whether these procedures are FDA approved. Technically, the FDA only approves drugs and devices. Were actually performing a surgical procedure and the FDA does not approve surgery. However, we are working with the FDA to have our system evaluated for potential FDA approval. Our initial FDA studies will be aimed at knee arthritis with the goal to show autologous SVF is more effective than a placebo. This will be done with a double blind controlled study. I doubt we will do FDA studies for every potential condition rather, doctors will ultimately gather data and/or do their own research and accumulate results to support the positive use of SVF for a large host of inflammatory and degenerative conditions.
Since starting our investigative network in 2012, weve not only gone to the animal lab for the Ommaya reservoir program, weve expanded our research into areas of cancer, paralysis, and most recently, concussion. My son, Sean, in fact, has been doing some terrific animal research in the area of concussion where hes been able to first, induce reproducible concussions in trained animals and show that they generally take two weeks to get better and re-learn their memory and motor skills; and second, by giving SVF via a tail vein injection after concussion, the rats get better so quickly that they regain their memory and motor skills right away. The implications for athletes, football especially, and the military are extraordinary.
There is a lot more information about our program that can be found at our website stemcellrevolution.com. Still, while this currently remains an area of investigation, it also represents one of the most exciting transitions in the field of medicine with tremendous potential now and in the future.
Read the latest news articles about Dr. Berman's Stem Cell work: Latest Stem Cell News about Dr. Berman
See the rest here:
Dr. Bermans's Stem Cell Therapy - Mark Berman MD
- 100 hospitals and health systems with great neurosurgery and spine programs | 2019 - Becker's Hospital Review - December 14th, 2019
- Therapeutic Exosomes Go From Vein to Brain - Technology Networks - December 13th, 2019
- Blinatumomab May Become New Standard of Care for Post-Reinduction Therapy in Young Patients With B-ALL - Cancer Therapy Advisor - December 13th, 2019
- Deacon Butch King learns to accept the 'gift' of cancer - Arkansas Catholic - December 13th, 2019
- How cancer cells grow and spread in colon tissue? - Tech Explorist - December 5th, 2019
- Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? - Kaiser Health News - December 5th, 2019
- Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer - PRNewswire - December 5th, 2019
- Analysis Shows Need for Better Classification of Rare Lymphoma - Patch.com - December 5th, 2019
- Aledo and Ennis will be a legendary regional final matchup, and not because of what's on the playing field - The Dallas Morning News - December 5th, 2019
- Volumetric Bioprinting: The New Paradigm in Regenerative Medicine - Advanced Science News - December 2nd, 2019
- Heres what you might have missed from the week in business - The Boston Globe - December 2nd, 2019
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire - November 29th, 2019
- The FutureAnd the End?of AIDS - Columbia University Irving Medical Center - November 29th, 2019
- Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market - P&T Community - November 29th, 2019
- ENCORE: Why There Are So Few Black Men In Medicine; Family of Stem Cell Donor Connects With Recipient 20 Years Later; Forecasting Volcanic Eruptions -... - November 26th, 2019
- Trial cancer treatment in Wichita - KAKE - November 26th, 2019
- Personalized Stem Cells, Inc. Sponsors Arthritis Foundation Event in Los Angeles - PR Web - November 26th, 2019
- BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York - P&T Community - November 26th, 2019
- AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore... - November 26th, 2019
- Fred Hutch at ASH: Latest CAR T data BCMA, CD19, CD20 plus new insights on transplantation, gene therapy and more - Newswise - November 22nd, 2019
- ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today - November 22nd, 2019
- Stem Cell Alopecia Treatment Market: moving from experimentation to transformation in 2024 - WindStreetz - November 22nd, 2019
- For veterans, theres no better cause to push than helping other vets - Snoqualmie Valley Record - November 18th, 2019
- What to Know in Washington: Trump Ally in Impeachment Spotlight - Bloomberg Government - November 18th, 2019
- Possible Treatment Found for Contractures in CP, Childhood Paralysis, Early Study Shows - Cerebral Palsy News Today - November 14th, 2019
- Asia's Top Firms Recognized at the 2019 Frost & Sullivan Asia-Pacific Best Practices Awards - Yahoo Finance - November 14th, 2019
- Takeda, Anderson Cancer Center team up for cell therapy - BSA bureau - November 11th, 2019
- Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform - BioSpace - November 11th, 2019
- Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And | CMAR - Dove Medical Press - November 8th, 2019
- An artist and a transplant researcher discuss the heart - Harvard Gazette - November 8th, 2019
- 2019s Allen Distinguished Investigators will focus on the mysteries of our cells - GeekWire - November 6th, 2019
- Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights - P&T Community - November 6th, 2019
- Cost is a major challenge in stem cells therapy: Dr Na'eem Sadiq - ETHealthworld.com - November 6th, 2019
- Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of... - November 6th, 2019
- Cardon Children's is proud of its 10-year history - East Valley Tribune - November 6th, 2019
- Celebrating Cancer Heroes will recognize survivors at event in Somers - Reminder Publications - November 6th, 2019
- Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Yahoo Finance - November 6th, 2019
- MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform - Newswise - November 6th, 2019
- Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune... - November 6th, 2019
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... - November 6th, 2019
- New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients - Bradford Era - November 5th, 2019
- VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web - November 5th, 2019
- Create a fetus without an egg or sperm? Researchers have done it with mice - Genetic Literacy Project - November 5th, 2019
- Cellular Biomedicine Group to Report Third Quarter 2019 Results on November 6, 2019 - Olean Times Herald - November 3rd, 2019
- Three UCLA scientists receive grants totaling more than $18 million - Newswise - October 31st, 2019
- Doheny and UCLA Stein Eye Institutes Welcome Kaustabh Ghosh, PhD, to the Scientific and Clinical Research Faculty - PRNewswire - October 31st, 2019
- bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Yahoo Finance - October 31st, 2019
- BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019 - PRNewswire - October 31st, 2019
- Introducing: iPSC Collection from Tauopathy Patients - Alzforum - October 24th, 2019
- Artificial embryo without sperm or egg forms live fetus - ZME Science - October 21st, 2019
- Novel Cell Sorting and Separation Markets, 2030 - Yahoo Finance - October 7th, 2019
- Platelet BioGenesis Receives Contract Worth Up to $56 Million from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human... - October 7th, 2019
- Researchers identify molecular process that could accelerate recovery from nerve injuries - UCLA Newsroom - October 7th, 2019
- A Therapeutic Counterblow to Traumatic Brain Injury - Technology Networks - October 7th, 2019
- American Cancer Society research breakfast highlights Colorado innovations changing the face of cancer care - The Know - October 7th, 2019
- UW Medicine receives $50 million donation to start brain institute - Lewiston Morning Tribune - October 5th, 2019
- UW Medicine receives $50 million donation to start institute to study addiction, Alzheimer's and more - The Daily World - October 5th, 2019
- American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND - Yahoo Finance - October 5th, 2019
- UW Medicine receives $50 million donation to start brain institute that will study addiction, Alzheimers and other brain disorders - Seattle Times - October 3rd, 2019
- Tenaya Therapeutics bags $92M to develop triple threat for heart disease - FierceBiotech - October 3rd, 2019
- Opinion: Primate research is cruel, expensive, unnecessary and happening here - OregonLive.com - October 3rd, 2019
- Giving a Speed Boost to Nerve Regrowth - Technology Networks - October 3rd, 2019
- Walking in His Shoes - Curetoday.com - October 3rd, 2019
- Into the Future With CAR-T Cell Therapy - Curetoday.com - October 3rd, 2019
- American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND - GuruFocus.com - October 3rd, 2019
- Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with... - October 3rd, 2019
- Skin-Cells-Turned-to-Heart-Cells Help Unravel Genetic Underpinnings of Cardiac Function - UC San Diego Health - October 1st, 2019
- AIVITA Biomedical to Present at Meeting on the Mesa and Other Investor, Oncology and Regenerative Medicine Conferences in October - PRNewswire - October 1st, 2019
- 3 Houston innovators to know this week - InnovationMap - October 1st, 2019
- Cord Stem Cell banking Market is Growing at a CAGR of 22.4% by Market Share and Growth with Top Key Players: National Cord Blood Program, Vita 34,... - September 24th, 2019
- How Cells Maintain Their Identity - Technology Networks - September 24th, 2019
- Mayo Clinic Q&A: Bone marrow transplants save lives more donors are needed - TribLIVE - September 24th, 2019
- After 'Hail Mary,' Leukemia Patient is in Remission With Help of Donor - Dana-Farber Cancer Institute - September 24th, 2019
- September Is Pediatric Cancer Awareness Month - Newswise - September 24th, 2019
- Guest view: Editors untimely death shines light on rare, incurable disease amyloidosis - Stockton Record - September 24th, 2019
- Steve Hunt's untimely death shines light on rare, incurable disease - VVdailypress.com - September 24th, 2019
- How to Get the Most from Stem Cell Therapy - Medical Center - September 16th, 2019
- Stem Cell Rejuvenation Center > About Us - September 16th, 2019
- Stem Cell Therapy Atlanta Home - Southern Stem Cell Institute - May 21st, 2019
- Stem Cell Therapy | Lighthouse Medical Center ... - April 25th, 2019